| INTRODUC TI ON
The presence of "preformed" antibodies specific against HLA before pediatric heart transplantation has been associated with high waitlist mortality, partially reflecting an historic requirement for negative donor-specific complement-dependent cytotoxicity crossmatch (CDC-XM). [1] [2] [3] [4] In contrast, transplantation across a positive CDC-XM may be associated with worse outcomes due to increased rejection, graft coronary vasculopathy, and graft dysfunction and failure. 3, [5] [6] [7] [8] In recent years, select centers have offered transplantation across a positive CDC-XM to sensitized candidates with a high risk of pretransplantation mortality. 1, [9] [10] [11] [12] Early results have been encouraging, even when retrospective CDC-XM was positive. However, optimal strategies for transplantation and management of sensitized pediatric heart candidates remain unknown, in part due to the challenges of drawing conclusions from small numbers of subjects in single-center studies.
Therefore, we developed a prospective, multicenter study to assess the impact of pretransplantation sensitization on pretransplantation and posttransplantation outcomes in pediatric heart candidates, focusing on the safety and efficacy of transplantation across a positive CDC-XM and the impact of donor-specific antibodies (DSAs) on posttransplantation outcomes. The study was developed within the infrastructure of the National Institutes of
Health (NIH)-sponsored Clinical Trials in Organ Transplantation in
Children (CTOTC) program (www.ctotc.org). The aims of this first CTOTC-04 report are to (1) describe study rationale and design, (2) report frequency and characterize pretransplantation alloantibodies by using contemporary solid-phase assays, and (3) define risk factors for sensitization in the study population.
| ME THODS

| Study design overview
This is a prospective, observational, multicenter cohort study of pediatric heart transplant candidates. The primary objective is to compare clinical outcomes of sensitized recipients with positive CDC-XM at transplantation (managed with a specialized treatment plan; see later) with the outcomes of nonsensitized recipients or sensitized recipients without positive CDC-XM (managed with standard immunosuppression). The primary hypothesis is that highly sensitized candidates with positive CDC-XM can achieve first-year outcomes similar to those of nonsensitized candidates when managed with perioperative antibody removal. Secondary objectives focused on outcomes based on assessment of DSAs, independent of CDC-XM results.
In addition, a series of mechanistic studies were designed to evaluate graft accommodation in the setting of circulating DSAs and for the development of a biomarker for antibody-mediated rejection based on evaluation of levels of cell-bound complement activation products in peripheral blood. A full description of the mechanistic studies is outside the scope of this report and will be detailed in future publications (see, also, www.clinicaltrials.gov for a summary of all study objectives and endpoints).
| Study organization and participating sites
The study was performed as part of a cooperative research program, CTOTC, sponsored by the National Institute of Allergy and Infectious
Diseases (NIAID). CTOTC is an investigative consortium for conduct-
ing multi-institutional clinical and associated mechanistic studies crossmatch, nonsensitized recipients, and sensitized recipients without positive crossmatch. Positive crossmatch recipients received antibody removal and augmented immunosuppression, while other recipients received standard immunosuppression with corticosteroid avoidance. This first CTOTC-04 report summarizes study rationale and design and relates pretransplantation sensitization status using solidphase technology. Risk factors for sensitization were explored. Of 317 screened patients, 290 were enrolled and 240 underwent transplantation. Core laboratory evaluation demonstrated that more than half of patients were anti-HLA sensitized.
Greater than 80% of sensitized patients had class I (with or without class II) HLA antibodies, and one-third of sensitized patients had at least 1 HLA antibody with median fluorescence intensity of ≥8000. Logistic regression models demonstrated male sex, weight, congenital heart disease history, prior allograft, and ventricular assist device are independent risk factors for sensitization.
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| Study duration
The planned study duration was 4 years, including 3 years of ac- 
| Diagnosis of sensitization and cohort assignment
Pretransplantation sensitization was first defined as positive Luminex LABScreen ® Mixed (LSM12) (One Lambda; Canoga Park, CA) for class I and/or class II with confirmation of the presence of HLA antibodies with median fluorescence intensity (MFI) ≥1000 by using Luminex LABScreen ® single-antigen (LSA) beads (One Lambda). To minimize false-negative results, the core laboratory subsequently performed LSA bead testing on all enrolled subjects, including those with negative LSM12 assay (see later). Local site results were used to assign nonsensitized patients to cohort A and patients sensitized to class I and/or class II HLA to cohort B. Cohort assignment status was used for evaluation of waitlist outcomes. Results from the Core Laboratory (with pretransplantation LSA testing of all subjects) were used to define subjects as "sensitized" or "nonsensitized" and are used for analysis of all posttransplantation outcomes in future reports.
Overall study design is summarized in the flow diagram in 
| Study procedures
Schedules for study visits and collection of blood and endomyocardial biopsy (EMB) samples are given online in Tables S1A
and S1B. Pretransplantation study visits occurred at enrollment (visit "PT1") and 6-month intervals until transplantation (visit 0).
Posttransplantation study visits occurred at posttransplantation days 1 and 7, months 1, 3, 6, 12, 24, and 36, and at initial posttransplantation hospital discharge.
| Participant selection and enrollment
Study inclusion and exclusion criteria are presented in (Table S1A ).
| Pretransplantation follow-up
Scheduled assessments before transplantation included chart review for new sensitizing events, change in UNOS listing status, and recent laboratory results. "Unscheduled visits" occurred with change in listing status or new sensitizing event. Delisted patients were followed for death or relisting.
| Day of transplantation
Before transplantation, patients were assigned to cohort A or B (as described here earlier) and blood specimens were obtained before any perioperative antibody removal (Table S1B) 
| Posttransplantation follow-up
Clinical data, blood for alloantibody analysis, EMB samples, and mechanistic study samples were obtained at regularly scheduled posttransplantation visits (Table S1B) 
| Study endpoints
The primary endpoint (Table 2 ) is a composite of the incidence of death, repeat transplantation, and rejection with hemodynamic compromise at 12 months posttransplantation. Table 2 and are assessed at 12 months posttransplantation as well as at subsequent follow-up to 3 years posttransplantation.
Secondary endpoints are listed in
| Alloantibody core laboratory
Samples of whole blood were sent at room temperature via over- All results refer to those from the Alloantibody Core Laboratory unless explicitly stated as local laboratory results. Donor and recipient molecular typing was by low-resolution molecular technique (including for HLA-C and -DQ) and was performed at local sites and entered into the CTOTC database. All donors and recipients were typed for DQB1* and, when possible, for DQA1*, and for DSA assignment we considered DQB1*/DQA1* pair based on DQA1* typing or DR/DQB1* association. There was variable availability of -DP molecular typing, and HLA-DP antibodies were assessed for DSA status only when donor and recipient DP typing was available. All DSA determinations were made by a single senior investigator (Core Director, A. Zeevi, University of Pittsburgh). 
| Immunosuppression management and clinical care guidelines
| Statistical considerations
We planned to enroll 370 subjects with an estimated 330 subjects 
| RE SULTS
| Patient characteristics
The consort diagram (Figure 2 ) follows the course of patients within the study. There were 317 screened patients at the 8 participating centers, and 290 were enrolled. Compared with enrolled patients, screen failures were similar in age, sex, and history of previous heart surgery but were more likely nonwhite/ nonblack race (33.3% vs 6.6%, P = .0005) and to have a diagnosis other than congenital heart disease (CHD) or cardiomyopathy (25.9% vs 2.1%, P < .0001). For enrolled patients ( 
| Sensitization status
Samples were available at the Alloantibody Core Laboratory for 272
of 290 patients at enrollment and 237 of 240 patients at transplan- 
Distribution of HLA antibody class and strength (based on MFI)
in transplanted patients is shown in Table 4 . There was little difference between enrollment and transplantation samples. In both cases, greater than 80% of patients had class I HLA antibodies (with or without class II). Almost half of patients had maximum MFI in the range of 1000 to 3999, but approximately one-third had at least 1 HLA antibody with peak MFI ≥ 8000. The majority (30 of 38, 78.9%) of the patients who had sensitization status "crossover" between enrollment and transplantation had peak MFI in the lowest range (1000-3999).
The breadth of anti-HLA was assessed by calculated panel reactive antibody, using the UNOS calculated panel reactive antibody calculator (https://www.unos.org/transplantation/allocationcalculators/) at the standard study definition of sensitization (MFI ≥ 1000) and with MFI cutoffs of ≥4000 and ≥8000 (Table 4) .
Antibody against MICA antigens was identified in 25 patients
at enrollment (9.2%) and transplantation (10.5%), respectively. This included 11.5% of the sensitized and 6.0% of the nonsensitized patients at enrollment and 14.7% of the sensitized and 5.6% of the nonsensitized patients at transplantation.
Overall, the proportion of sensitized subjects was similar between the local and core laboratories (59.6% vs 54.4%, respectively).
Of 97 nonsensitized patients by local laboratory testing, 70 (72.2%)
were nonsensitized and 27 (27.8%) were sensitized by core laboratory testing (no available core laboratory sample in 3 patients). Of 143 sensitized patients by local laboratory testing, 102 (71.3%) were sensitized and 38 (26.6%) were nonsensitized by core laboratory testing (no available core laboratory sample in 3 patients). Overall, there was discordance between local and core laboratories in 27.4% of patients. Of the discordant samples, sensitization was associated with low peak MFI (1000-3999) in the majority (86.8%) of cases.
| Risk factors for sensitization
Patient characteristics for enrollment and transplantation samples stratified by sensitization status are shown in Table 5 . Univariable analyses demonstrated sensitization at enrollment associated with heavier weight (20.5 vs 15.6 kg, P = .0287), black race (25.0% vs 15.5%, P = .0087), male sex (61.5% vs 46.6%, P = .0140), being listed as an outpatient (35.3% vs 24.1%, P = .0489), prior heart surgery (66.0% vs 45.7%, P = .0008), blood transfusion (64.1% vs 45.7%, P = .0025), aortic or pulmonary allograft placement (21.8% vs 9.5%, P = .0069), and heart transplantation (9.6% vs 0.9%, P = .0024).
When examining sensitization status at transplantation, the significant associations remained the same except that race was no longer significant and CHD diagnosis (52.7% vs 34.3%, P = .0047) was associated with sensitization. Prior sensitizing events were more common in patients with CHD than cardiomyopathy (99.2% vs 59.3%). Strength of sensitization (peak MFI) differed between patients with cardiomyopathy and patients with CHD. The majority (62.9%) of sensitized patients with cardiomyopathy had peak MFI of 1000 to 3999, which was true of only 36.6% of sensitized patients with CHD. of sensitized patients with HLA antibodies of high strength (peak MFI ≥ 8000) identified the risk factors prior transplantation (OR 58.410, P < .0001), diagnosis of CHD (OR 6.288, P = .0008), history of use of a ventricular assist device (VAD) (OR 4.282, P = .0047), and prior allograft (OR 3.004, P = .0229).
| D ISCUSS I ON
Sensitization among pediatric patients considered for heart transplantation presents a significant challenge, and controversy exists regarding optimal strategy for pretransplantation and posttransplantation management. Furthermore, there is no consensus on criteria for donor selection, even when candidate antibody status is known and donor HLA typing is available. Almost all prior studies in this area are limited to single-center reports or registry data. 3, 4, 8, [15] [16] [17] [18] [19] [20] [21] [22] There have been no prior prospective, multi-institutional studies that address these issues in the pediatric heart transplant population. Furthermore, the methods of detection of anti-HLA have evolved from the initial cell-based CDC-PRA assays to newer solidphase, flow-bead techniques such as the Luminex ® assay that mix patient serum with latex beads bound with single HLA. This has enabled the identification of individual anti-HLA specificities with much greater sensitivity and determination of relative strength, enhancing accuracy of VXM before organ acceptance. 23, 24 This approach has proved to be a strong predictor of a positive CDC-XM at transplantation 23, 25 and is used practically by many institutions to guide donor organ acceptance. 26 However, this may come at the cost of increased wait times and waitlist mortality for sensitized candidates. 2, 9 Several centers in the CTOTC-04 consortium had previously noted through retrospective evaluation that transplantation in the setting of a positive donor-specific CDC-XM can be achieved with similar early posttransplantation survival. [9] [10] [11] [12] This led us to hypothesize that sensitized pediatric heart candidates with positive CDC-XM can achieve outcomes similar to nonsensitized candidates when managed with perioperative antibody removal and augmented immunosuppression. We further hypothesized that the use of donor organs regardless of VXM and CDC-XM results would reduce waitlist mortality. In this first report from the CTOTC-04 study, we aimed to outline in detail our study rationale and design for future reference, report the frequency and characterization of pretransplantation alloantibodies using contemporary solid-phase assay, and define risk factors for sensitization in the study population. An accompanying report describes the primary study clinical outcomes. 
| Frequency of pretransplantation sensitization
Previous reports in pediatric patients found pretransplantation sensitization rates between 14% and 23% by using a definition of T and/or B cell CDC-PRA greater than 10%. 1, 3, 26 In our population, defining sensitization as positive Luminex ® screen and detection of at least 1 anti-HLA with MFI ≥ 1000 identified by single antigen bead testing, we identified a higher frequency of sensitization. More than half of candidates were sensitized, and among sensitized candidates approximately one-third had 1 or more anti-HLA with peak MFI ≥ 8000, a value considered to represent concern for early poor graft outcomes in other transplant populations.
28-30
The reasons for the unexpectedly high number of sensitized patients are likely several. We anticipated higher prevalence of sensitized patients compared with historic cohorts evaluated by CDC-PRA because the solid-phase platforms are known to be more sensitive.
Furthermore, with no identified singular significant cutoff for sensitization defined in the literature, 31 we chose to err on the side of being more inclusive and define sensitization at an MFI cutoff of 1000 .0849
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Weight at listing, median kg (IQR) TA B L E 5 (Continued) because one of the future directions of this consortium is to determine the importance of low strength preformed alloantibodies on outcomes after transplantation. In particular, it will be important to define the appropriate criteria for excluding donors during the performance of a VXM, especially when identified DSAs are present at low strength.
At low MFI, it may be difficult to distinguish "false-positive" findings from findings that are real but potentially clinically unimportant. Also contributing to high rates of sensitization is the large proportion of patients in this cohort with CHD (48.2%), with the vast majority of these patients having had a prior sensitizing event, which was not surprising
given that the majority of these patients underwent previous surgical palliation(s). However, the number of patients with cardiomyopathy who had a prior sensitizing event was surprisingly high (59.3%), reflecting, in part, the increasing use of VAD as a bridge to transplantation in pediatrics, which accounted for more than half of these events.
| Risk factors for sensitization
While our results demonstrate a greater frequency of pretransplantation sensitization than have prior studies, risk factors for sensitization mostly remain the same. These include CHD with prior cardiac surgery (especially allograft placement), male sex, weight at transplantation, and VAD use. Prior heart transplantation was the strongest predictor of sensitization. There were only minor differences in the models depending on the MFI threshold used to define sensitization, with male sex and weight identified as risk factors for sensitization ≥1000 MFI but not at higher strength (≥8000 MFI), whereas VAD use was only a risk factor for sensitization at higher strength anti-HLA.
| Study limitations
We enrolled fewer patients than originally planned, but this study still represents the largest cohort of pediatric heart transplant candidates enrolled in a prospective study. The final enrollment will influence the power of the primary outcome 27 but still provides a rich dataset for analysis of the frequency, antibody characteristics, and risk factors for pretransplantation sensitization in the contemporary era. We recognize that antibody characterization is limited to class and strength in this initial analysis. Predictive value for clinical outcomes may be enhanced by more-detailed characterization of pretransplantation antibodies such as analysis of immunoglobulin class and isotype, as well as subtype, dilutional analysis of sera, and complement fixing ability. Such studies are currently under way. This study addresses only pretransplantation sensitization status. Future studies will also focus on the predictive value of detection of de novo DSAs posttransplantation in the large cohort of patients who achieved transplantation within CTOTC-04.
| CON CLUS ION
The use of solid-phase assay demonstrated that sensitization against HLA is more common in children requiring heart transplantation than previously reported. Traditional risk factors associated with sensitization are identified in the current study, although we have further modeled risk factors based on HLA antibody strength. Longer-term follow-up of this large group of wellphenotyped patients offers a unique opportunity to understand the role played by these alloantibodies on late outcomes. Future analyses will provide invaluable information as to risk stratification, including how to optimally perform donor organ selection and the role played by VXM. 
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